Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYP-1901 vs Aflibercept in Wet AMD
NCT06683742Phase 3Active, not recruiting
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of vorolanib in exudative macular degeneration (2 arms), sponsored by EyePoint Pharmaceuticals. Primary endpoint: Best Corrected Visual Acuity at 56 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
vorolanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06683742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683742.